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Abstract
Background: Insensitivity of advanced-stage prostate cancer to androgen ablation therapy is a serious problem in clinical
practice because it is associated with aggressive progression and poor prognosis. Targeted therapeutic drug discovery efforts
are thwarted by lack of adequate knowledge of gene(s) associated with prostate tumorigenesis. Therefore there is the need for
studies to provide leads to targeted intervention measures. Here we propose that stable expression of U94, a tumor suppressor
gene encoded by human herpesvirus 6A (HHV-6A), could alter gene expression and thereby inhibit the tumorigenicity of PC3
cell line. Microarray gene expression profiling on U94 recombinant PC3 cell line could reveal genes that would elucidate prostate
cancer biology, and hopefully identify potential therapeutic targets.
Results: We have shown that stable expression of U94 gene in PC3 cell line inhibited its focus formation in culture, and
tumorigenesis in nude mice. Moreover gene expression profiling revealed dramatic upregulation of FN 1 (fibronectin, 91 ± 16-
fold), and profound downregulation of ANGPTL 4 (angiopoietin-like-4, 20 ± 4-fold) in U94 recombinant PC3 cell line. Quantitative
real-time polymerase chain reaction (QRT-PCR) analysis showed that the pattern of expression of FN 1 and ANGPTL 4 mRNA
were consistent with the microarray data. Based on previous reports, the findings in this study implicate upregulation of FN 1
and downregulation of ANGPTL 4 in the anti tumor activity of U94. Genes with cancer inhibitory activities that were also
upregulated include SERPINE 2 (serine/cysteine protease inhibitor 2, 7 ± 1-fold increase) and ADAMTS 1 (a disintegrin-like and
metalloprotease with thrombospondin type 1 motif, 7 ± 2-fold increase). Additionally, SPUVE 23 (serine protease 23) that is pro-
tumorigenic was significantly downregulated (10 ± 1-fold).
Conclusion: The dramatic upregulation of FN 1 and downregulation of ANGPTL 4 genes in PC3 cell line stably expressing U94
implicate up-regulation of FN 1 and downregulation of ANGPTL 4 in anti tumor activity of U94. Further studies are necessary to
determine functional roles of differentially expressed genes in U94 recombinant PC3 cell line, and hopefully provide leads to
potential therapeutic targets in prostate cancer.
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Background
Prostate cancer is the most common form of malignancy
in US males. An estimated 29,900 fatalities out of 230,110
new cases are expected in the year 2004 [1]. Androgen
ablation is currently the mainstay in prostate cancer ther-
apy, but its efficiency is marred by the relapse of some
advanced-stage prostate cancer cells into an androgen
refractory state [2,3]. Advanced-stage prostate cancer pro-
gression is usually aggressive and correlates with poor
prognosis [2,4,5]. Hence, insensitivity to androgen abla-
tion by advanced-stage prostate cancer invariably consti-
tutes a major problem in clinical therapy. Therefore there
is an urgent need for the development of targeted thera-
peutic strategies in advanced-stage prostate cancer.
Knowledge of the genes that are associated with prostate
cancer is important for designing an effective therapeutic
strategy. However, present knowledge of the molecular
biology of prostate cancer is inadequate to define etiologic
genes [5-7]. Consequently, current therapeutic strategies
in prostate cancer are inefficient [8-20], and an effective
targeted therapy remains elusive. This situation prompted
our laboratory to embark on studies to provide alternative
leads for the development of efficacious and targeted anti
prostate cancer agent(s). In our approach, we investigated
the anti tumor activity of U94 protein (U94) in prostate
cancer cell line, PC3.
U94 is a 1473 bp gene located in the HD12 fragment of
human herpesvirus 6A (HHV-6A), strain U1102 [21]. U94
encodes a 490 amino acid protein that is not found in
other herpesviruses [21,22], and U94 is expressed at very
low levels [23,24]. Recent reports suggest that U94 is a
latency gene, and modulates viral DNA replication [23-
26]. Moreover, structural homology of U94 to Rep 78/68
from adeno-associated virus type 2 (AAV-2) [21,27] sug-
gests that there might be functional similarities between
these proteins. Strong evidence in support of functional
similarities between U94 and Rep 78/68 is the observa-
tion that U94 complemented the replication of an AAV-2
mutant that was deficient in Rep 78/68 [28]. Additionally,
recent reports show that U94 also inhibits gene transcrip-
tion [29], which is a biological function of its homologue
Rep78/68. However, U94 may affect gene transcription
differently than Rep 78/68, because U94 activates human
immunodeficiency virus 1 (HIV-1) long terminal repeat
(LTR) promoter in fibroblast cell lines [28] and inhibits
HIV-1 LTR in T-cell lines [29], whereas Rep 78/68 inhibits
HIV-1 LTR promoter in both fibroblast cell lines and T-cell
lines [28].
Previous studies demonstrated that U94 suppressed trans-
formation by oncogenes [22,29]. Data from these studies
showed that an NIH 3T3 cell line stably expressing U94
gene suppressed transformation by the oncogene H-ras,
when compared to the parental NIH 3T3 cell line treated
under similar conditions [29]. We were motivated by the
findings in previous studies to determine the anti tumor
potential of U94 in the human prostate tumor cell line
PC3.
In this paper we report that the expression of U94 protein
in PC3 cells inhibited foci formation (Figure 2; Table 1),
and the tumorigenicity of recombinant PC3 cell line in
athymic nude mice (Figure 3). Moreover, gene expression
analyses (Figures 4 and 5), and QRT-PCR (Table 2)
revealed dramatic upregulation of FN 1 (~91-fold) and
profound downregulation of ANGPTL 4 (~20-fold) in 2
separate recombinant PC3 cell lines stably expressing
U94. Our study also demonstrated the differential expres-
sion pattern of several other genes in the presence of U94.
This is the first study to report the inhibitory potential of
U94 on the tumorigenicity of advanced-stage prostate
cancer cell line PC3.
Results
Previously, we have demonstrated that U94 inhibited
gene transcription and also transformation by oncogenes
[22,29]. Several reports have implicated the malfunction
of transcription regulatory factors [30-38] as well as the
activities of oncogenes [39-48] as etiologic factors in pros-
tate tumorigenesis. Hence we wanted to determine
whether U94 could exert inhibitory activity on the tumor-
igenesis of PC3 cell line.
Expression and intracellular localization of U94 protein
First, we wanted to determine whether U94 could be
expressed in PC3 cell line. We transfected PC3 cell line
with plasmid pBKU94, which contained U94 DNA insert
and a selectable geneticin (G418)-resistant vector cassette.
pBKCMV vector transfected PC3 cells served as control.
Immunoblot analyses, using the U94 polyclonal antibody
AB679 as depicted in Figure 1, showed that U94 (56 kDa)
protein was expressed in the nuclear fraction (lane 3) and
not the cytoplasmic fraction (lane 2) of stably transfected
PC3 cell line. No immunoreactivity was detected in the
nuclear fraction of vector transfected PC3 cell line (lane
1). Figure 1 lane 4 shows the high molecular weight Rain-
bow marker.
Inhibition of focus formation by U94 protein expression
In order to monitor the effect of U94 on tumor formation,
we investigated focus formation by PC3 cell line as an
index of a neoplastic phenotype. Focus formation was
observed as dense foci of intensive cell growth in culture,
consisting of refractive cells that rounded up and piled on
top of each other [49]. Three PC3 cell lines were used in
this study: U94  transfected, vector cassette transfected,
and parental PC3 cell line. For each cell line, 1 × 106 cells/
60 mm culture dish was seeded and grown to confluence.Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
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Focus formation was examined 10 days post confluence.
The result of this study (Table 1) showed a drastic reduc-
tion in focus formation by PC3 cells expressing U94: the
number of foci were reduced ~35-fold and 40-fold in
comparison with the control vector transfected and paren-
tal PC3 cell lines, respectively. Figure 2 shows large and
widespread foci in the culture of control vector transfected
and parental PC3 cell lines. The culture of recombinant
PC3 cell line expressing U94 protein showed only few
foci, grossly reduced in size. Our findings suggest that U94
may exhibit anti tumor activity in vitro.
Expression of U94 inhibits tumorigenicity of PC3 cell line 
in athymic nude mice
In order to determine whether U94 inhibits the tumori-
genicity of PC3 cell line in vivo, we inoculated 5 × 106 PC3
cells (U94 transfected cells as test, or vector cassette trans-
fected cells as control) subcutaneously behind the neck,
into athymic nude mice. Animals were examined for
tumor formation on days 7, 14, 17, 21, and 28 after inoc-
ulation. Our result showed that tumor formation was
inhibited in mice that were inoculated with PC3 cell line
stably expressing U94 protein (Figure 3). The control ani-
mals that were inoculated with PC3 cell line transfected
with vector cassette developed tumors, and tumor size
increased progressively with time as shown in Figure 3.
Statistical analysis, using a repeated measures analysis of
variance (ANOVA), demonstrated that tumor volume in
test and control animals were significantly different (P <
0.05). A comparison of tumor volume between test and
control mice, using Paired Student's t-test to supplement
ANOVA, further showed that the average tumor volume of
test and control animals were significantly different (P <
0.05) on each day tumor volumes were determined. These
findings demonstrate that U94 significantly (P < 0.05)
inhibited the tumorigenicity of PC3 cell line in athymic
nude mice, and corroborate our data (Figure 2) from
focus formation assay.
Microarray gene expression profiling in PC3 cell line stably 
expressing U94
We performed microarray gene expression profiling on
recombinant PC3 cell line stably expressing U94 to deter-
mine whether U94 affected expression of genes involved
in tumorigenesis. We used two clones of U94  recom-
binant PC3 cell lines as test samples, and PC3 cell line
transfected with plasmid vector as our reference. The effect
of U94 on gene expression was analyzed using two-color
comparative fluorescence assays on glass slide microarrays
containing ~6,000 cancer related genes. Our data demon-
strated the differential expression of 78 genes: 31 genes
were upregulated (Figure 4) while 47 genes were down-
regulated (Figure 5). These results show the mean values
for two clones of U94  recombinant PC3 cell lines.
Notably, the microarray results revealed dramatic upregu-
lation of FN 1 (91 ± 16-fold), and profound downregula-
tion of ANGPTL 4 (20 ± 4-fold) in PC3 cell lines stably
expressing U94 protein. Although a majority of the differ-
entially expressed genes showed a 2–3 fold change in
expression level in the presence of U94, we decided to
consider for further studies only genes with ≥ 6-fold
change. The microarray data is deposited in the Gene
Expression Omnibus of the NCBI, and is available at the
NCBI web site http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=ncbisearch.
Immunoblot of U94 protein Figure 1
Immunoblot of U94 protein. Nuclear and cytoplasmic 
protein was extracted from confluent PC3 cell line, PC3 cell 
line transfected with vector cassette (controls) or PC3 cell 
line transfected with plasmid containing U94 DNA (test). 100 
µg sample protein was loaded per lane and separated by 
SDS-PAGE through a 10% Tris-glycine gel (Novex; Invitro-
gen, Gaithersburg, MD). The results showed the 56 kDa U94 
protein in the nuclear extract of U94 recombinant cells. 
There was no immunoreactivity in all cytoplasmic extracts, 
and nuclear extracts of control cells. U94 protein was 
detected using the polyclonal anti-U94 antibody, AB679 
(Amersham, England). The positions of 46 kDa and 66 kDa 
markers, and the U94 protein are indicated on the right.Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
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Quantitative real-time PCR
We performed QRT-PCR to confirm the microarray data.
In one clone of U94 recombinant PC3 cell line, the QRT-
PCR data (Table 2) showed that the changes in expression
levels of FN 1 and ANGPTL 4 mRNA were 183 ± 27-fold
increase and 76 ± 13-fold decrease, respectively. In the sec-
ond clone of U94 recombinant PC3 cell line, the corre-
sponding changes in expression levels were 467 ± 32-fold
increase and 67 ± 5-fold decrease, respectively. The
observed differences in the fold changes between the
microarray and QRT-PCR data may be due, at least in part,
to differences in detection sensitivity of the two tech-
niques, as well as the subtle differences in experimental
conditions and physiological conditions in the microen-
vironment of the cells in culture. Nevertheless, the trend
observed from QRT-PCR data was consistent with the
trend from microarray data. Additionally, the results from
both techniques showed elevation of SERPINE 2 and
ADAMTS 1 expressions (Table 2 and Figure 4), and down-
regulation of SPUVE 23 (Table 2 and Figure 5). TGM-2
(transglutaminase 2) showed 8 ± 2-fold decrease by
microarray, but we did not perform QRT-PCR.
Discussion
In the present study, we have demonstrated for the first
time that U94 protein inhibited focus formation and tum-
origenicity of the prostate cancer cell line PC3. This study
is particularly interesting because PC3 cell line is a deriva-
tive of advanced-stage prostate cancer metastasis to bone
and is insensitive to androgen ablation therapy. Insensi-
tivity to androgen ablation therapy is associated with
aggressive progression of the cancer, and ultimately fatal
in less than 24 months [2,6]. Therefore the anti tumor
activity of U94 in PC3 cell line is novel and interesting,
and may have a translational application.
The impetus for our study on anti tumor activity of U94 in
PC3 cell line was given by previous findings [22,29] that
U94 suppressed transformation by oncogenes. Appar-
ently, U94 shares this functional activity with its homo-
logue Rep 78/68 of AAV-2 [24]. However, the
mechanism(s) of transformation suppressor activity is not
understood. A previous report showed that U94 lost its
activity when translation termination linkers were
inserted at codons 25, 125 and 245 of its nucleotide
sequence [29]. This finding implicates U94 protein
expression in anti tumor activity in recombinant PC3 cell
line. Therefore we performed immunoblot analysis and
demonstrated that U94 protein (56 kDa) was expressed,
and localized to the nucleus (Figure 1, lane 3) in PC3 cell
line. Nuclear localization of U94 protein suggests that
U94 might exert activity, probably on gene expression, in
the nucleus of PC3 cell line. This view is in consonance
with previous findings [22,29] that U94 inhibited gene
expression. A previous study [29] showed that U94 sup-
pressed the P97 promoter, which controls the expression
of the E6 and E7 transforming genes of human papilloma-
virus 16 (HPV-6). Therefore we suspect that the tumor
suppressor activity of U94 in our study was exerted by
inhibition of gene expression. It is interesting to note that
Inhibition of focus formation by PC3 cell line stably expressing U94 protein Figure 2
Inhibition of focus formation by PC3 cell line stably expressing U94 protein. PC3 cell line transfected with plasmid 
containing U94 DNA was used for studies. The controls were PC3 cell line transfected with vector cassette or parental PC3 
cell line. 1 × 106 cells/ 75 cm2 culture flask was grown to confluence, and focus formation was examined 10 days after. Panel A: 
PC3 cells (negative control); Panel B: PC3 cells transfected with vector cassette (vector control); Panel C: PC3 cells stably 
expressing U94 protein (test). Control cells formed foci (Panel A and Panel B) consisting of rounded refractive cells piling on 
top of each other. Notice that the expression of U94 protein (Panel C) inhibited focus formation. (Magnification: 20X on 
Olympus CK2 microscope, Olympus Optical Co. Ltd. Japan).
foci
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the expression of U94 protein does not affect the growth
pattern of NIH 3T3 cell line [29]. This observation is sup-
ported by another report [25] that lymphoid cells stably
expressing U94 had the same morphology and growth
characteristics as parental cell line. Thus previous findings
suggest that U94 is not toxic to cells, and we speculate that
the same would be true for the PC3 cell line.
In the current investigation, we examined the effect of sta-
ble expression of U94 protein on focus formation, a
malignant phenotype, by recombinant PC3 cell line.
Focus formation by PC3 cell line stably expressing U94
was inhibited drastically (~30- to 40-fold) in comparison
to that of control parental and vector transfected cell lines
(Table 1). As shown in Figure 2, widespread and large foci
were formed by control PC3 cell lines in contrast to back-
ground foci formed by U94 recombinants. It is possible
that the few foci observed in the background originated
from spontaneous transformation and/ or leakage during
clonal selection. Furthermore, our studies demonstrated
that the anti cancer activity of U94 was sustainable in vivo
as tumor development was significantly (P < 0.05) inhib-
ited in mice that were treated with U94 recombinant PC3
cell line (Figure 3). Previous studies linked prostate malig-
nancy to the activities of oncogenes [39-48]. Therefore the
inhibition of focus formation and tumorigenicity in our
study supports the hypothesis that U94 probably inhib-
ited oncogenic activities in prostate cancer cell line PC3,
and thereby exhibited anti cancer activity. Our microarray
data identified FN 1 that was dramatically elevated (~91-
fold) (Figure 4) and ANGPTL 4 that was profoundly
reduced (~20-fold) (Figure 5) as genes of interest in this
study. Up-regulation of FN 1 in the current study was actu-
ally unexpected because previous reports [22,29]
suggested that U94 inhibited gene expression. In contrast,
our findings suggested that U94 actually altered gene
expression in PC3 cell line positively or negatively.
Although it is not known how U94 mediated gene expres-
sion, our data is interesting because ANGPTL 4 is pro-ang-
iogenic [50], and reduced expression could negatively
impact tumorigenesis. Additionally, previous reports [51-
54] implicated elevated FN 1 and/ or its derivatives in par-
adigms of tumor inhibition.
Fibronectin (FN) is a major component of extracellular
matrix (ECM), where it is assembled as insoluble poly-
mers, and is present in the blood as a soluble dimer [55].
Fibronectin 1 (FN 1) is a homologue of FN, and contains
a self-assembly domain, which induces FN 1-FN 1 polym-
erization [56-58]. Therefore the terms FN 1 and FN are
used interchangeably in regard to polymerization in this
report.
FN 1-FN 1 interaction is reported [59,60] to induce con-
formational changes that increase the binding ability of
FN 1 to receptor(s). We speculate that the tremendous
upregulation of FN 1 transcription in the presence of U94
led to elevated translation and secretion of protein prod-
uct in PC3 cells. The increased level of FN 1 protein in turn
accelerated FN 1-FN 1 polymerization [56-58]. We sus-
pect that polymeric FN 1 binding to PC3 cell surface mit-
igated malignant signaling [61]. The potential anti-
malignancy activity of FN 1 is evident from a recent report
[62] that exogenous FN 1 could reverse transformed
phenotype. Hence, FN 1 interaction with PC3 cell surface
might have contributed, at least in part, to inhibition of
focus formation in vitro (Figure 2) and tumorigenesis in
vivo (Figure 3).
Strong support for in vivo anti tumor activity of polymeric
FN 1 is given by a previous report [53] demonstrating that
systemic administration of polymeric FN 1 exhibited anti
tumor activity in mice bearing various types of tumors.
Tumorigenicity of U94 recombinant PC3 cell line in nude  mice Figure 3
Tumorigenicity of U94 recombinant PC3 cell line in 
nude mice. Stable G418 resistant cell lines were generated 
by transfection of PC3 cells with either pRc-RSV (vector con-
trol) or pRc-U94 (test). Confluent cells (5 × 106 cells/100 
µl), in culture medium without antibiotics or serum were 
inoculated behind the neck into athymic nude mice (Ncr nu/
nu), and monitored for tumor production. Tumor size was 
measured on days 7, 14, 17, 21 and 28 post inoculation. Data 
from two animal experiments (experiment 1: n = 3 per 
group; and experiment 2, n = 4 per group) were pooled. The 
average tumor volume in cubic centimeters was plotted 
against time in days. The error bars represent standard devi-
ation. Notice the significant reduction in tumor size in ani-
mals inoculated with U94 recombinant PC3 cell line. A 
repeated measures analysis of variance demonstrated a signif-
icant difference (P < 0.05) in tumor volume between test and 
control animals. Additionally, paired Student's t-test showed 
a significant difference in average tumor size of test animals in 
comparison to control animals.Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
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Further support is provided by a recent report [59] show-
ing that anastellin, a component of FN 1 that is capable of
inducing FN 1-FN 1 polymerization, displays anti ang-
iogenic and anti metastastic properties in vivo. Addition-
ally, other workers [52] have demonstrated that peptides
of FN 1 exert anti tumor activity in vivo. These findings
provide a rational explanation for the observation in this
study that elevated FN 1 expression in U94 recombinant
PC3 cell line is associated with anti tumor activity. Taken
together, previous reports [52,53,59] lend credence to our
view that binding of polymeric FN 1 to PC3 cells surface
induces the inhibition of focus formation in culture and
Upregulated genes in PC3 cell line stably expressing U94 Figure 4
Upregulated genes in PC3 cell line stably expressing U94. Two clones of G418 resistant PC3 cell lines transfected with 
plasmid pBk-U94 (tests 1 and 2) and a clone transfected with plasmid pBK-CMV (reference) were used for cDNA microarray 
studies. Each experiment was performed in triplicate and the results are mean ± SD. Notice the dramatic upregulation of FN 1 
(91 ± 16-fold). A subset of other genes was also upregulated, but genes of interest in this study (> 6-fold change) include: SER-
PINE 2 (7 ± 1-fold); and ADAMTS 1 (7 ± 2-fold).Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
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inhibition of tumorigenicity in mice. However, in
addition to FN 1, our results also implicated ANGPTL 4 in
the anti tumor activity of U94 in PC3 cell line.
Downregulated genes in PC3 cell line stably expressing U94 Figure 5
Downregulated genes in PC3 cell line stably expressing U94. Data presented here were generated as reported in Fig-
ure 4. Notice the pronounced down-regulation of angiogenic gene, ANGPTL4 (20 ± 4-fold). Additional genes that were signifi-
cantly downregulated, and with a fold change > 6, include: SPUVE 23 (10 ± 1-fold); TGM 2 (8 ± 2-fold).Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
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ANGPTL 4 was shown in a chicken chorioallantoic mem-
brane assay to induce a strong pro-angiogenic response,
independent of VEGF  gene [50]. Since angiogenesis is
implicated in vascular development, and neovasculariza-
tion is the hallmark of tumor progression [63,64], an
inhibitor of angiogenesis could greatly impact tumor ther-
apy. In the current study we have demonstrated that
ANGPTL 4 was profoundly inhibited (downregulated
about 20-fold) in U94 recombinant PC3 cell line. It is
therefore expected that downregulation of ANGPTL 4
would exert a negative effect on vascular development,
and thereby inhibit PC3 cell line tumorigenicity in vivo.
Although it is not clear how U94 mediates the expression
of ANGPTL 4, recent reports [65-67] show that angiogen-
esis is regulated by ECM signals. Interestingly, other
reports [53,59] suggest that the anti-angiogenic property
of polymeric FN 1 is mediated by induction of ECM sig-
nals. Therefore, it appears that there may be a casual or
causal relationship between anti tumor activity of poly-
meric FN 1 and the inhibition of ANGPTL 4 in  U94
recombinant PC3 cell line. Since ANGPTL 4 supports vas-
cular development [50], we speculate that ANGPTL 4 did
not mediate the inhibition of focus formation by PC3 cell
line in this study.
In addition to FN 1 and ANGPTL 4, we also chose for fur-
ther studies a subset of other genes that expressed differ-
entially > 6-fold. Genes in this category included SERPINE
2 (elevated ~7-fold), ADAMTS 1 (upregulated ~7-fold)
and  SPUVE 23 (downregulated ~10-fold). SERPINE 2
encodes a serine proteinase inhibitor, and was recently
implicated in anti cancer activity [68]. ADAMTS 1 is an
active metalloproteinase associated with ECM [69]. It is
essential for normal growth [70], but also displays anti-
angiogenic activity [71]. In consonance with previous
reports [68,71], data from the current study suggest that
SERPINE 2 and ADAMST 1 probably exerted anti tumor
activity. Previous studies [72,73] showed that the expres-
sion of SPUVE 23, a serine protease, is associated with
increased malignant potential. Therefore we propose that
downregulation of SPUVE 23 in U94 recombinant PC3
cell line is tantamount to anti tumor activity.
In conclusion, the findings in this study have suggested
that U94 exhibits anti tumor potential in PC3 cell line.
The dramatic elevation of FN 1 expression and reduction
of ANGPTL 4 expression in U94 recombinant PC3 cell
line can be interpreted as evidence of the mechanism of
U94 anti tumor activity. Therefore data from our study
seem to support the anti tumor hypothesis of FN 1 previ-
Table 1: Inhibition of focus formation by prostate cancer cell line PC3 expressing U94 protein.
Cell line No. of foci/75 cm2flask
Parental PC3 cell line 80
Vector transfected PC3 cell line 69
PC3 cell line stably expressing U94 2
Clonal PC3 cell lines, transfected with plasmid containing U94 gene and geneticin (G418) resistant cassette, were used for studies. PC3 cell line 
transfected with vector cassette or parental PC3 cell line served as controls. G418 resistant clones were sub-cultured and grown to confluence. 
Focus formation was detected as dense foci of actively growing and refractive cells. The experiment was performed in duplicate, and the average 
number of foci was reported. Notice that stable expression of U94 drastically inhibited focus formation.
Table 2: Fold changes of differentially expressed genes in PC3 cell line stablyexpressing U94.
PC3/U94 Clones FNI SERPINE2 ADAMTS1 ANGPTL4 SPUVE23
Microarray
1 & 2 91 ± 16 7 ± 1 7 ± 2 -20 ± 4 -10 ± 1
QRT-PCR
1 183 ± 27 3 ± 1 4 ± 1 -76 ± 13 -6 ± 1
2 467 ± 33 7 10 ± 1 -67 ± 5 -9
Differential expression of genes was determined by microarray, and QRT-PCR was used to confirm microarray data. Microarray data were 
computed from array analyses presented in Figures 4 and 5. For QRT-PCR, a subculture of PC3 cell lines used for microarray was used for studies: 
2 clones of U94 transfected PC3 cells and vector transfected PC3 cells. The protocol for total RNA extraction was same as for microarray studies, 
except that the RNA extracts were treated with DNase 1. QRT-PCR was performed in triplicate, using SYBR® Green I chemistry, on 7900 HTS 
Sequence Detection System (Applied Biosystems, Foster City, CA) according to manufacturer's instructions. The results are presented as average 
of 3 experiments ± SD. Notice that Microarray data and QRT-PCR data show similar trends; moreover the trend of QRT-PCR results was 
reproducible in 2 clones of U94 recombinant PC3 cell lines.Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
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ously reported by other workers [51,52,54,55,74]. Moreo-
ver, this report identifies ANGPTL 4 and SPUVE 23 as
potential therapeutic targets in prostate tumorigenesis.
Hopefully, further studies on the microarray data reported
herein might elucidate the complex genetic alterations
that underlie advanced-stage prostate tumorigenesis, and
thereby provide leads for defining targeted therapeutic
strategies for advanced-stage prostate cancer.
Materials and methods
Cells and transfection
PC3 cell line was purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and plasmid U94
DNA was prepared as previously described [22,29]). All
cells were cultured in HAM's F12 medium (Cell gro/Medi-
atech, VA, USA) supplemented with 2 mM glutamine, 100
U of penicillin-streptomycin per ml (Invitrogen, Gaithers-
burg, MD, USA), and 10% Fetal Bovine Serum (FBS,
HyClone, Logan, UT, USA), at 37°C and 5% CO2. Plas-
mid U94 DNA was cloned into the HindIII site of pRc-RSV
vector (Invitrogen, Gaithersburg, MD, USA) or HindIII/
BamHI site of pBK-CMV (Stratagene, Cedar Creek, TX,
USA) vector. Both pRc-RSV and pBK-CMV vectors contain
a geneticin (G418; Mediatech Inc, Herndon, VA, USA)
selectable marker. U94 DNA sequence in the constructs
was confirmed by DNA sequencing. The pBK-U94 con-
struct was specifically used in experiments that necessi-
tated strong expression of U94 protein e.g.
immunoblotting, because previous findings showed that
U94 mRNA and protein were expressed at very low levels
[23,24,75]. All plasmid DNA were prepared by double-
banded cesium chloride gradient ultracentrifugation. U94
construct (pRc-U94 or pBK-U94), or plasmid vector cas-
sette (pRc-RSV or pBK-CMV) was used for transfection of
PC3 cells. For transfections, 5.5 × 105 PC3 cells were
plated in 60 mm culture dish, and grown over-night
(50%-70% confluence). Transfection was performed by
the calcium phosphate-based ProFection Mammalian
Transfection method (Promega, Madison, WI, USA) in
accordance with manufacturer's protocol. Stably
transfected PC3 cells were selected with G418 (600 µg/
ml), and expanded to establish U94 recombinant PC3 cell
line. Clonal selection was performed on G418 resistant
healthy colonies using a clonal cylinder. In order to min-
imise culture driven genetic changes [76], transfected cells
were discarded after 8 passages.
Protein extraction, and immunoblot analysis
Nuclear fraction from cellular extract was prepared as
described previously [77]. Confluent PC3 cell line (107-
1.5 × 107 cells), stably expressing U94 and resistant to
G418 antibiotic (Cellgro, Herndon, VA, USA) was freshly
prepared by trypsinization, washed with DMEM (Cellgro/
Mediatech, VA, USA), suspended in 50 ml DMEM (in ster-
ile 50 ml centrifuge tube), and incubated at 37°C/ 5%
CO2 for 2 hours. Cells were centrifuged at 200 × g for 5
minutes, and resuspended in 0.5 ml phosphate buffered
saline (PBS, Biofluids, Rockville, MD, USA) in microfuge
tube. The cell pellet from another round of centrifugation
was resuspended in 400 µl of Buffer A (10 mM HEPES; 10
mM KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM DTT; o.5
mM PMSF; 1% v/v aprotinin). After incubation at 40°C
for 15 minutes, cells were lysed by adding 0.6% Nonidet
P-40, mixed by inverting tube 10 times, and the nuclei was
obtained by centrifugation at 200 × g for 5 minutes. The
supernatant was used as the cytoplasmic fraction. The
nuclei were resuspended gently in ice-cold 100 µl of
Buffer B (20 mM HEPES; 0.4 M NaCl; 1 mM EDTA; 1 mM
DGTA; 1 mM DDT; 1 mM PMSF; 1% v/v aprotinin; 10%
glycerol), using a wide bore pipette. The nuclei lysate was
incubated in a rotary shaker for 30 minutes at 4°C, and
then centrifuged at 12000 × g for 10 minutes. To aliquots
of the clear supernatant in microfuge tubes, 0.025 mg/ml
leupeptin was added before storage at -80°C. The control
cell lines: vector transfected and resistant to G418, and
parental PC3, were similarly treated.
Protein determination in the extracts was performed using
BCA protein assay kit (Pierce, Rockford, IL, USA). Follow-
ing sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE), resolved proteins were
electroblotted onto polyvinylidene difluoride (PVDF)
membrane. The membrane was blocked in 5% non-fat
milk solution on a rocker for 30 min, and rinsed quickly
Table 3: Sequences of Forward and Reverse primers for gene amplification in QRT-PCR.
Genes Forward Primer Reverse primer
FN 1 5-GTGTGACCCTCATGAGGCAAC-3 5-CTGGCCTCCAAAGCATGTG-3
SERPINE 2 5-CACATCAGCACCAAGACCATAGAC-3 5-TGCCAAGAACTTTCAGCGG-3
ADAMST 1 5-CCAGCGTATCTTGCCAGTAACC-3 5-TTTGCAACTGGCAGTTTACTCTG-3
ANGPTL 4 5-CCACTTGGGACCAGGATCAC-3 5-CGGAAGTACTGGCCGTTGAG-3
SPUVE 23 5-CCCAGTCTACCCTCAATTTAGCC-3 5-GCAGTGGAGTTCCCTTATGACAC-3
Gene specific primers for QRT-PCR were designed using Primer Express Version 2.0 (Applied Biosystems, Foster City, CA) according to the 
sequence information provided for the cDNAs on the microarray.Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
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in Tris/sodium chloride/EDTA/Tween 20 (TNET, 0.2 M
Tris pH 7.5; 0.05 M EDTA; 1.0 M NaCl; 1% Tween 20)
wash solution. Then the membrane was washed twice in
TNET on a rocker for 10 minutes, before it was probed
with U94 primary antibody AB679 (Rabbit antiserum,
1:1000 dilution in TNET; Amersham) on a rocker for 1
hour. This was followed by three 10-minutes washes in
TNET before anti rabbit-HRP-tagged secondary antibody
(1:10,000 dilution in TNET; Amersham) was added and
incubated for 1 hour. Three 10-minutes washes in TNET
were performed on a rocker, before the detection of
immunoreactive proteins using ECL (Amersham, Eng-
land) reagent.
Focus formation assay
Two clones of U94 transfected cell lines were used for
studies. Vector transfected and parental PC3 cell lines
were used as controls. Cells were plated at 1 × 106 cells/ 75
cm2 culture flask in duplicate and grown to confluence.
Focus formation was visually detected by observing dense
foci of intensive cell growth, consisting of refractive cells
that rounded up and piled on top of each other [49]. The
number of foci in each flask was noted on the 10th day
after the cells were confluent. Average counts of foci in
duplicate flasks were determined for each cell type.
Tumorigenicity assay
The tumorigenicity of PC3 cell line stably expressing U94
was tested in athymic Ncr nu/nu mice. The control animals
were treated with vector transfected PC3 cell line. In all
cases 5 × 106 cells were inoculated subcutaneously behind
the neck, into athymic nude mice as earlier described [78].
The mice were monitored every 2 or 3 days for the appear-
ance of tumors, and tumor volume was measured on days
7, 14, 17, 21 and 28 post inoculation. Tumor sizes were
evaluated by tumor volume (length × width × height, in
cm). In all cases confluent cells were used. There were two
animal experiments. In the first (n = 3 per group), data
entries were made on days 0, 7, 17, 21, and 28, while in
the second (n = 4 per group) entries were made on days 0,
7, 14, and 17 post inoculation. Data were pooled from the
two experiments and reported. The Animal Welfare Com-
mittee, Georgetown University, approved the protocol for
the animal studies.
Total RNA extraction and purification
Two clones of PC3 cell line stably expressing U94 (test
samples 1 and 2) and PC3 cell line transfected with vector
cassette (reference sample) were used for studies. Cells
were grown to confluence and total RNA was extracted
using Trizol reagent (Invitrogen, Gaithersburg, MD) fol-
lowing manufacturer's instructions. The RNA was cleaned
up using the RNeasy® mini columns (Qiagen, Valencia,
CA, USA) following manufacturers' instructions. RNA
content and quality was initially determined by OD260and
OD280 measurements. RNA samples showing an OD260/
280 ratio higher than 1.8 was used for microarray hybridi-
zation and QRT-PCR. RNA content and integrity was reas-
sayed in duplicate using the Bioanalyzer 2100 (Agilent,
Germantown, MD, USA).
Microarray analysis
Gene expression analysis was performed using a 6 k
human cDNA microarray fabricated with ~6000 cancer
related genes. Fifty micrograms of total RNA from test and
reference samples were separately reversed transcribed
using the MicroMax™ Direct cDNA Labeling Kit (Perkin
Elmer Life Sciences, Boston, MA, USA) into Cy3 and Cy5
labeled cDNA targets. Cy3-labeled targets prepared from
test samples 1 and 2 were hybridized with Cy5-labeled
cDNA targets from reference sample onto separate micro-
arrays. A dye-swapping experiment was performed with
cDNA targets from test sample 1 labeled with Cy5 and
cDNA targets from reference sample labeled with Cy3 in
order to eliminate any experimental bias owing to the dif-
ferences in incorporation efficiency of the 2 fluorescent
dyes. Thus the microarray hybridization was carried out in
triplicate. Labeled test and reference cDNAs were pooled
and purified using Microcon YM-100 filter units (Milli-
pore Corp., Bedford, MA, USA), and co-hybridized onto
the microarray at 65°C for 14 hours in the dark. Each
microarray was washed at room temperature in 45 ml of
the respective wash buffer with the following composition
and for the specified duration: 1x SSC/ 0.2% SDS for 5
minutes; 0.5x SSC/ 0.01% SDS for 15 minutes; 0.06x SSC/
0.01% SDS for 15 minutes; 0.06x SSC for 15 minutes. The
washed microarrays were spun at 1000 rpm for 4 minutes
before scanning at 5 micron resolution using the ScanAr-
ray 5000XL (Packard Biosciences, Billerica, MA, USA). Sig-
nals generated from Cy3 and Cy5 channels on each
microarray were background subtracted and normalized
to the total signals of all spots by LOWESS method, and
analyzed by ScanArray Express software (Perkin Elmer Life
Sciences, Boston, MA, USA). Data were represented as a
fold change of fluorescence intensity of a gene from test
sample versus reference sample. A fluorescence intensity
ratio of U94/vector transfected targets ≥ 2 represented up-
regulation of gene; while ≤ 0.5 represented down-regula-
tion. Average values and standard deviation for triplicate
experiments were determined. Genes were considered to
be differentially expressed only if they displayed the same
trend of change in expression in each of the triplicate
experiments. Gene annotation information was based on
the human Unigene Cluster Build #161 (5th of June 2003;
NCBI)
Quantitative real-time polymerase chain reaction (QRT-
PCR)
To verify the expression pattern of the differentially
expressing genes identified from microarray experiments,Cancer Cell International 2005, 5:19 http://www.cancerci.com/content/5/1/19
Page 11 of 13
(page number not for citation purposes)
QRT-PCR was performed as described previously (79).
Equal amounts of total RNA from test and reference cell
lines were treated with DNase 1 (Invitrogen, Gaithers-
burg, MD, USA), and reverse transcribed using random
hexamers and SuperScript II (Invitrogen, Gaithersburg,
MD, USA) to prepare the first strand cDNA samples for
QRT-PCR analyses. The RT product was diluted 5-fold,
and 1 µl is equivalent to 1x concentration. Gene specific
primers (Table 3) were designed by Primer Express Ver-
sion 2.0 (Applied Biosystems, Foster City, CA, USA)
according to the sequence information provided for the
cDNAs on the microarray. The primers were BLASTed
against the non-redundant and EST mouse sets from
NCBI to confirm specificity. QRT-PCR was performed in
triplicate using SYBR® Green I chemistry on 7900 HTS
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) according to manufacturer's instructions.
The temperature cycle for QRT-PCR was set up as
following: 50°C for 2 minutes; 95°C for 10 minutes;
95°C 15 seconds and 60°C for 1 minute for 40 cycles. A
final dissociation cycle running at 95°C for 15 seconds,
60°C for 15 seconds and 95°C for 15 seconds was set up
for monitoring the specificity of amplification. The rela-
tive standard curve method was used for quantifying gene
expression level, in which the CT values of a series of fixed
amounts of test sample (or reference sample) cDNAs
(0.01x , 0.1x and 1x as described above) were plotted
against these amounts of cDNAs. The CT value for a gene
at 0.1x concentration in the reference sample (or test sam-
ple) was fitted onto the standard curve to obtain the
respective expression level. A smaller CT value indicates a
higher expression level, and vice versa. Genes showing CT
values ≥ 40 were considered to be non-expressing. The
final gene expression data were reported after normalising
to that of 18S RNA.
Statistical analysis
A repeated measures analysis of variance (ANOVA), sup-
plemented by Paired Student's t-test, was used to evaluate
the differences in tumor volume between U94 treated and
control vector treated mice. A value of p < 0.05 was con-
sidered statistically significant. SAS software (v8.2, SAS
Institute, Cary, NC, USA) was used for ANOVA. Experi-
mental data, where applicable, are represented as mean ±
SD.
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